



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Zalutumumab

Cat. No.:	HY-P99155
CAS No.:	667901-13-5
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Zalutumumab is a high affinity, completely human IgG1 monoclonal antibody targeting EGFR. Zalutumumab binds to domain III of the EGF receptor and acts by blocking the binding of EGF and by sterically interfering with the active conformation of the receptor. Zalutumumab binds with IgG and its Fab fragment with EC <sub>50</sub> s of 7 and 19 nM, respectively. Zalutumumab can be used for the research of cancer <sup>[1][2][3]</sup> .								
<b>In Vitro</b>	<p>Zalutumumab (0-1 μM; 60 min) effectively blocks EGF-induced EGFR activation with an IC<sub>50</sub> value of 1.3 nM<sup>[2]</sup>. Zalutumumab (0-1 μM; 96 h) affects proliferation of A431 cells<sup>[2]</sup>. Zalutumumab (10 μg/mL; 24 h) induces a comparable percentage of specific lysis of A431 cells with mouse macrophages<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>A431 cell line</td> </tr> <tr> <td>Concentration:</td> <td>0-1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>96 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited A431 cells proliferation with an IC<sub>50</sub> value of 1.5 nM.</td> </tr> </table>	Cell Line:	A431 cell line	Concentration:	0-1 μM	Incubation Time:	96 hours	Result:	Inhibited A431 cells proliferation with an IC <sub>50</sub> value of 1.5 nM.
Cell Line:	A431 cell line								
Concentration:	0-1 μM								
Incubation Time:	96 hours								
Result:	Inhibited A431 cells proliferation with an IC <sub>50</sub> value of 1.5 nM.								
<b>In Vivo</b>	<p>Zalutumumab (5 mg/kg; i.p. 2 h after tumor induction) affects tumor growth in A431 xenograft models<sup>[3]</sup>. Zalutumumab (0.5 and 5 mg/kg; i.p. once ) delays tumor growth when mice with tumor volumes of 80-100 mm<sup>3</sup><sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>SCID mice with A431 cells injection<sup>[3]</sup></td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 5 mg/kg 2 hours after tumor induction</td> </tr> <tr> <td>Result:</td> <td>Effectively inhibited tumor growth in A431 xenograft models with an early treatment.</td> </tr> </table>	Animal Model:	SCID mice with A431 cells injection <sup>[3]</sup>	Dosage:	5 mg/kg	Administration:	Intraperitoneal injection; 5 mg/kg 2 hours after tumor induction	Result:	Effectively inhibited tumor growth in A431 xenograft models with an early treatment.
Animal Model:	SCID mice with A431 cells injection <sup>[3]</sup>								
Dosage:	5 mg/kg								
Administration:	Intraperitoneal injection; 5 mg/kg 2 hours after tumor induction								
Result:	Effectively inhibited tumor growth in A431 xenograft models with an early treatment.								

### REFERENCES

---

[1]. Schick U, et al. Zalutumumab in head and neck cancer. *Expert Opin Biol Ther.* 2012 Jan;12(1):119-25.

[2]. Lammerts van Bueren JJ, et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. *Proc Natl Acad Sci U S A.* 2008 Apr 22;105(16):6109-14.

[3]. Overdijk MB, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. *J Immunol.* 2011 Sep 15;187(6):3383-90.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA